Animal pharmaceuticals manufacturer AML Riverside is gearing up to inject $11 million in an expansion of its Fort Dodge, IA production plant, the company told The Fort Dodge Messenger. 16 new roles will be created at the site through the investment.
The funds will be used to add a dispensing room, space for processing activities, and large granulation equipment, the newspaper’s coverage detailed. A company official said in the Messenger that AML Riverside’s decision to expand the site stems from a recent R&D project for a client.
Work on the plant is expected to reach completion in 2024.
AML Riverside is part of global contract research organization (CRO) and contract development and manufacturing organization (CDMO) Argenta Global. Earlier this month, Argenta named Matt Applegate as general manager of the Fort Dodge plant.
